342 related articles for article (PubMed ID: 37330926)
21. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.
Sbidian E; Chaimani A; Guelimi R; Garcia-Doval I; Hua C; Hughes C; Naldi L; Kinberger M; Afach S; Le Cleach L
Cochrane Database Syst Rev; 2023 Jul; 7(7):CD011535. PubMed ID: 37436070
[TBL] [Abstract][Full Text] [Related]
22. Comparative safety and benefit-risk profile of biologics and oral treatment for moderate-to-severe plaque psoriasis: A network meta-analysis of clinical trial data.
Shear NH; Betts KA; Soliman AM; Joshi A; Wang Y; Zhao J; Gisondi P; Sinvhal R; Armstrong AW
J Am Acad Dermatol; 2021 Sep; 85(3):572-581. PubMed ID: 33631216
[TBL] [Abstract][Full Text] [Related]
23. The Effectiveness of Risankizumab Following Guselkumab Failure in Moderate-to-Severe Psoriasis Patients: A Retrospective Study.
Hamm C; Ramsoondar N; McGillis M; Waugh M; Gooderham M; Giroux LL
J Cutan Med Surg; 2023; 27(5):476-480. PubMed ID: 37559454
[TBL] [Abstract][Full Text] [Related]
24. Guselkumab versus secukinumab for the treatment of moderate-to-severe psoriasis (ECLIPSE): results from a phase 3, randomised controlled trial.
Reich K; Armstrong AW; Langley RG; Flavin S; Randazzo B; Li S; Hsu MC; Branigan P; Blauvelt A
Lancet; 2019 Sep; 394(10201):831-839. PubMed ID: 31402114
[TBL] [Abstract][Full Text] [Related]
25. Structural basis for differential p19 targeting by IL-23 biologics.
Daniele SG; Eldirany SA; Ho M; Bunick CG
bioRxiv; 2023 Mar; ():. PubMed ID: 36945513
[TBL] [Abstract][Full Text] [Related]
26. Update on risankizumab for the treatment of moderate to severe psoriasis.
Al-Janabi A; Warren RB
Expert Opin Biol Ther; 2020 Nov; 20(11):1245-1251. PubMed ID: 32933320
[TBL] [Abstract][Full Text] [Related]
27. Guselkumab, Risankizumab, and Tildrakizumab in the Management of Psoriasis: A Review of the Real-World Evidence.
Ruggiero A; Picone V; Martora F; Fabbrocini G; Megna M
Clin Cosmet Investig Dermatol; 2022; 15():1649-1658. PubMed ID: 35996400
[TBL] [Abstract][Full Text] [Related]
28. Short-term risk and long-term incidence rate of infection and malignancy with IL-17 and IL-23 inhibitors in adult patients with psoriasis and psoriatic arthritis: a systematic review and meta-analysis.
Wu S; Xu Y; Yang L; Guo L; Jiang X
Front Immunol; 2023; 14():1294416. PubMed ID: 38106423
[TBL] [Abstract][Full Text] [Related]
29. Real-world effectiveness of anti-interleukin-23 antibodies in chronic plaque-type psoriasis of patients from the Austrian Psoriasis Registry (PsoRA).
Graier T; Weger W; Jonak C; Sator P; Zikeli C; Prillinger K; Sassmann C; Gruber B; Saxinger W; Ratzinger G; Painsi C; Mlynek A; Häring N; Sadoghi B; Trattner H; Müllegger R; Quehenberger F; Salmhofer W; Wolf P
Sci Rep; 2022 Sep; 12(1):15078. PubMed ID: 36064563
[TBL] [Abstract][Full Text] [Related]
30. Drug safety evaluation of tildrakizumab for psoriasis: a review of the current knowledge.
Ruggiero A; Camela E; Potestio L; Fabbrocini G; Megna M
Expert Opin Drug Saf; 2022 Dec; 21(12):1445-1451. PubMed ID: 36527300
[TBL] [Abstract][Full Text] [Related]
31. Pathophysiology, Clinical Presentation, and Treatment of Psoriasis: A Review.
Armstrong AW; Read C
JAMA; 2020 May; 323(19):1945-1960. PubMed ID: 32427307
[TBL] [Abstract][Full Text] [Related]
32. Short-term effectiveness of biologics in patients with moderate-to-severe plaque psoriasis: A systematic review and network meta-analysis.
Tada Y; Watanabe R; Noma H; Kanai Y; Nomura T; Kaneko K
J Dermatol Sci; 2020 Jul; 99(1):53-61. PubMed ID: 32600737
[TBL] [Abstract][Full Text] [Related]
33. Risankizumab in Adults with Psoriatic Arthritis.
Machlab K; Yeung J; Gooderham M
Skin Therapy Lett; 2023 Nov; 28(6):1-6. PubMed ID: 38015960
[TBL] [Abstract][Full Text] [Related]
34. Real world practice indirect comparison between guselkumab and risankizumab: Results from an Italian retrospective study.
Ruggiero A; Fabbrocini G; Cinelli E; Megna M
Dermatol Ther; 2022 Jan; 35(1):e15214. PubMed ID: 34800070
[TBL] [Abstract][Full Text] [Related]
35. Guselkumab for the Treatment of Psoriasis.
Machado Á; Torres T
BioDrugs; 2018 Apr; 32(2):119-128. PubMed ID: 29470778
[TBL] [Abstract][Full Text] [Related]
36. Guselkumab: an anti-IL-23 antibody for the treatment of moderate-to-severe plaque psoriasis.
Chiricozzi A; Costanzo A; Fargnoli MC; Malagoli P; Piaserico S; Amerio P; Argenziano G; Balato N; Bardazzi F; Bianchi L; Carrera CG; Conti A; Dapavo P; De Simone C; Loconsole F; Lo Schiavo A; Malara G; Musumeci ML; Parodi A; Peris K; Prignano F; Rongioletti F; Talamonti M; Potenza C
Eur J Dermatol; 2021 Feb; 31(1):3-16. PubMed ID: 33648915
[TBL] [Abstract][Full Text] [Related]
37. Selective Interleukin-23 p19 Inhibition: Another Game Changer in Psoriasis? Focus on Risankizumab.
Torres T
Drugs; 2017 Sep; 77(14):1493-1503. PubMed ID: 28770513
[TBL] [Abstract][Full Text] [Related]
38. Drug Survival of Interleukin (IL)‑17 and IL‑23 Inhibitors for the Treatment of Psoriasis: A Retrospective Multi‑country, Multicentric Cohort Study.
Torres T; Puig L; Vender R; Yeung J; Carrascosa JM; Piaserico S; Gisondi P; Lynde C; Ferreira P; Bastos PM; Dauden E; Leite L; Valerio J; Del Alcázar-Viladomiu E; Rull EV; Llamas-Velasco M; Pirro F; Messina F; Bruni M; Licata G; Ricceri F; Nidegger A; Hugo J; Mufti A; Daponte AI; Teixeira L; Balato A; Romanelli M; Prignano F; Gkalpakiotis S; Conrad C; Lazaridou E; Rompoti N; Papoutsaki M; Nogueira M; Chiricozzi A
Am J Clin Dermatol; 2022 Nov; 23(6):891-904. PubMed ID: 35976568
[TBL] [Abstract][Full Text] [Related]
39. A Systematic Literature Review and Bucher Indirect Comparison: Tildrakizumab versus Guselkumab.
Du Jardin KG; Hurtado Lopez P; Lange M; McCool R; Maeso Naval S; Quickert S
J Health Econ Outcomes Res; 2020; 7(2):123-129. PubMed ID: 32766377
[TBL] [Abstract][Full Text] [Related]
40. Tildrakizumab for the treatment of psoriasis.
Bangert C; Kopp T
Immunotherapy; 2018 Sep; 10(13):1105-1122. PubMed ID: 30081696
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
